GLUT3 is predominantly localized on neuronal and cardiomyocyte membranes, where it facilitates energy metabolism in these cells
The Perilipins: Major cytosolic lipid droplet-associated proteins and their roles in cellular lipid storage
Key Market Highlights The global GLP-1 analogues market was valued at US$ 51.6 Billion in 2024 The market is expected to reach US$ 211.8 Billion by 2035 The industry is forecast to expand at a CAGR of 13.7% during 2025-2035 North America accounted for the largest market share of 68.4% in 2024 The Subcutaneous route of administration segment held 78.2% market share in 2024 Major industry participants include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and AstraZeneca Rising Type 2 Diabetes Cases Accelerating Market Growth The growing prevalence of type 2 diabetes remains one of the most significant growth drivers for the GLP-1 analogues market
Whether a coach personally supports or questions about GLP-1 use, effective health coaching requires neutrality
Overview: Where GLP-1 Litigation Stands Now As of 2026, GLP-1 drug litigation is in an active investigation and litigation and early case-building phase , with: growing numbers of individual claims coordinated legal review across jurisdictions increasing focus on severe gastrointestinal and organ injuries, NAION and Vision loss expanding expert and scientific analysis litigating the consolidated proceedings in state and federal court GLP-1 Lawsuit status update, July 6th, 2026 There have been no reported GLP-1 lawsuit settlements
